Customize your JAMA Network experience by selecting one or more topics from the list below.
Ross JS, Madigan D, Konstam MA, Egilman DS, Krumholz HM. Persistence of Cardiovascular Risk After Rofecoxib Discontinuation. Arch Intern Med. 2010;170(22):2035–2036. doi:10.1001/archinternmed.2010.461
Interim results from the Adenomatous Polyp Prevention on Vioxx (APPROVe) trial demonstrated that rofecoxib was associated with an increased risk of cardiovascular events,1 leading to Merck's withdrawal of rofecoxib from the worldwide market in September 2004. In October 2008, long-term follow-up findings were published2; during a 1-year period of postdrug observation, increased cardiovascular risk associated with rofecoxib use persisted after stopping treatment.
These findings raise concerns about long-term risks incurred by individuals who had taken the drug. Data from only 1 other rofecoxib clinical trial, study 078,3 provides information about long-term off-drug cardiovascular risk after clinical trial drug discontinuation. Accordingly, our objective was to examine whether increased cardiovascular risk of rofecoxib persisted after stopping treatment in study 078.
Create a personal account or sign in to: